Home > About BNE > Press Room > Current Articles > February

Roswell Park Researchers Publish Findings on Agent Shown to Enhance Immunotherapy

Conclusions from study of entinostat combination to be tested in kidney, prostate cancer clinical trials

MEDIA CONTACT: 

Annie Deck-Miller, Senior Media Relations Manager
716-845-8593; annie.deck-miller@roswellpark.org

Thursday, February 23, 2012

BUFFALO, NY — Preclinical research by a team from Roswell Park Cancer Institute (RPCI) has demonstrated for the first time the way in which a class I histone deacetylase (HDAC) inhibitor, entinostat, appears to boost the effectiveness of cancer immunotherapy for treatment of some solid tumors. The findings support conclusions from earlier studies and also suggest that the approach merits further testing in clinical settings.

In a study involving models of renal and prostate cancer, recently published in the peer-reviewed scientific journalPLoS One, a team led by Roberto Pili, MD, Professor of Oncology, Chief of the Genitourinary Section and Co-leader of the Genitourinary Program, Department of Medicine, demonstrated the novel immunomodulatory effect through which entinostat, manufactured by Syndax Pharmaceuticals, Inc., appears to enhance the antitumor activity of Interleukin-2 (IL-2) for kidney cancer and of a survivin cancer vaccine (SurVaxM), developed at RPCI by Michael Ciesielski, PhD, and Robert Fenstermaker, MD, of the Department of Neurosurgery, for prostate cancer.

“Entinostat has an immunomodulatory effect on regulatory T cells, which are like brakes for the immune system and are present in many tumors,” Dr. Pili explains. “By suppressing these suppressor cells, entinostat releases the brakes and helps the immunotherapies to work better.”

The combination of a vaccine with approaches to deplete or suppress regulatory T cells, the researchers write, “represents a rational strategy in prostate cancer therapy” and one that “also has promising potential to be effective in other immunotherapies and in different tumors.”

Li Shen, PhD, a postdoctoral associate in the Department of Medicine, was lead author on the study. Drs. Ciesielski and Fenstermaker were also contributing authors, as were Swathi Ramakrishnan, Kiersten M. Miles, PhD, Leigh Ellis, PhD, and Paula Sotomayor, Department of Medicine; and Protul Shrikant, PhD, Department of Immunology.

The PLoS One article is titled “Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models,” and can be accessed online at:http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0030815.

A clinical study testing the combination of entinostat with IL-2 in renal-cell cancer is underway at RPCI and other sites. For more information about that study, which is currently accruing participants, go to: http://www.roswellpark.org/clinical-trials/list/145208-0.

Additional clinical studies of the combination of entinostat and other immunotherapies are planned in prostate cancer and other solid tumors.

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. RPCI, founded in 1898, was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit RPCI’s website at http://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci@roswellpark.org.

2 Canadian Companies get Help to Move Here

Mar-02-2012 — Two Canadian companies are moving to Western New York, with help from Buffalo Niagara Enterprise.

Medical Research Building Will Benefit Patients and the Region

Feb-27-2012 — The stage is set for some important medical advances at the University at Buffalo's Clinical and Translational Research Center (CTRC). The new UB facility will be housed in the top four floors of the new $291 million joint UB-Kaleida Health building now under construction at Goodrich and Ellicott streets on the Buffalo Niagara Medical Campus.

Schumer, Higgins Push Feds to Fund 'Launch New York' Initiative

Feb-27-2012 — New York Senator Charles E. Schumer and New York Congressman Brian Higgins on Tuesday urged the Commerce Department and the Economic Development Administration to support the application and provide funding for a new Venture Development Organization called “Launch New York”.

2 Roswell Park Faculty Receive Prestigious Awards

Feb-27-2012 — Roswell Park Cancer Institute (RPCI) faculty members have been selected to receive prestigious honors from their colleagues in recognition of their professional achievements

Roswell Park Again Included on ‘Great Oncology Programs’ List

Feb-27-2012 — Roswell Park Cancer Institute (RPCI) has once again been included on Becker’s Hospital Review’s annual list of centers that serve as leaders in cancer research, prevention, treatment and education.

Firms win $700,000 for energy research

Feb-22-2012 — A state agency is awarding $700,000 to two Buffalo-area companies that are developing environmentally friendly technology to generate electricity while reducing the use of fossil fuels that produce pollution

Megawatts up at Steel Winds

Feb-22-2012 — The six new wind turbines at the former Bethlehem Steel complex along the Lake Erie shoreline have started generating electricity

UB Works to Promote Faculty Inventions, Services

Feb-21-2012 — Research universities across the country are working to find the most effective and efficient ways to make the transfer from faculty innovations to economic growth. At the University at Buffalo, several departments including UB STOR, UB CAT and the Center of Excellence are turning technology transfer into an economic engine for the region.

Webster Block on Developers' Radar

Feb-17-2012 — Developers will get a crack at a prized downtown parcel before the end of the month. Proposals for what's known as the Webster Block, a 1.9-acre, city-owned parcel in front of First Niagara Center, will soon be sought, Mayor Byron W. Brown said Wednesday.

M&T Adding Jobs, Office Space

Feb-17-2012 — Buffalo-based M&T has leased 21,000-square-feet in a vacant 40,000-square-foot office building on John Glenn Drive in the Audubon Industrial Park where it will house more than 200 employees in its mortgage-servicing division. The John Glenn Drive space is less than one-quarter mile from a data operation M&T operates at the corner of Sweet Home Road and Commerce Drive.

Cambria Technology Park Site Officially Ready To Attract Business

Feb-13-2012 — CAMBRIA — While it has historically been known for its agriculture, the bucolic Town of Cambria is now ready to attract high-tech business to its southeast corner.

50th anniversary in store for Tops

Feb-10-2012 — As a tie-in with its 50th anniversary, Tops Friendly Markets has started the first wave of what will be a year-long celebration.

TOPS FRIENDLY MARKETS LAUNCHES YEAR-LONG 50TH ANNIVERSARY CELEBRATION

Feb-10-2012 — Tops Friendly Markets, a leading full-service grocery retailer in upstate New York and northern Pennsylvania, announced today that the company will commemorate its 50th anniversary with a year-long celebration. As part of the anniversary celebration, Tops will offer shoppers new promotions, exceptional savings, contests and events throughout the year.

Home sales warm to the weather

Feb-09-2012 — Western New York’s housing market benefited from warm weather and newfound confidence among homeowners and buyers in December, as sales rose 4.2 percent, while the number of homes newly listed for sale jumped 13 percent.

RPCI, UB spinoff takes simulator to Sweden

Feb-03-2012 — A Buffalo biotechnology company has begun selling its product internationally, completing a sale in Stockholm, Sweden.

Donation in name of Holm could net UB $2M

Feb-03-2012 — University officials announced the match-challenge donation Monday. The donor, who has already contributed $250,000, has agreed to match, dollar for dollar, all donations of $10,000 or more up to $1 million, a UB spokesperson said. That means the gift total could be as much as $2 million.

S.B.A. Readying Program to Invest in Start-Ups

Feb-03-2012 — The S.B.A. unveiled a new $1 billion program to invest in young companies by loaning money to venture capital funds.

FDA approves drug to treat cystic fibrosis

Feb-03-2012 — The first drug that treats the cause of cystic fibrosis in some patients gained approval Tuesday, offering a major advance to many individuals with the disease.